Compare TGTX & RGTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGTX | RGTI |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | 164 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.9B |
| IPO Year | 2008 | N/A |
| Metric | TGTX | RGTI |
|---|---|---|
| Price | $51.02 | $20.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $49.80 | $30.78 |
| AVG Volume (30 Days) | 1.9M | ★ 56.1M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $2,785,000.00 | N/A |
| Revenue This Year | $49.08 | $225.06 |
| Revenue Next Year | $26.69 | $99.56 |
| P/E Ratio | $421.42 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.37 | $11.01 |
| 52 Week High | $50.80 | $58.15 |
| Indicator | TGTX | RGTI |
|---|---|---|
| Relative Strength Index (RSI) | 80.09 | 49.01 |
| Support Level | $28.57 | $14.52 |
| Resistance Level | N/A | $27.34 |
| Average True Range (ATR) | 2.19 | 2.26 |
| MACD | 1.06 | -0.46 |
| Stochastic Oscillator | 96.97 | 24.92 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.